Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Comparison of the In Vitro Antifibrogenic Effects of Silymarin, Silybin A and 18α-Glycyrrhizin on Activated Hepatic Stellate Cells

Seyed Younes Hosseini 1 , 2 , Kurosh Kalantar 3 , Khashayar Shahin 2 , Maryam Ghayour 2 , 4 , Masoumeh Rajabi Bazl 4 , Mohammad-Reza Fattahi 2 , Maryam Moini 2 and Zahra Amirghofran 3 , 5 , *
Authors Information
1 Department of Bacteriology and Virology, Shiraz University of Medical Sciences, Shiraz, Iran
2 Gastroenterohepatology Research Center (GEHRC), Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran
4 Departement of Clinical Biochemistry, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
5 Autoimmune Disease Research Center and Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: November 2017, 12 (4); e40285
  • Published Online: November 7, 2016
  • Article Type: Research Article
  • Received: June 22, 2016
  • Revised: September 17, 2016
  • Accepted: October 31, 2016
  • DOI: 10.5812/jjnpp.40285

To Cite: Hosseini S Y, Kalantar K, Shahin K, Ghayour M, Rajabi Bazl M, et al. Comparison of the In Vitro Antifibrogenic Effects of Silymarin, Silybin A and 18α-Glycyrrhizin on Activated Hepatic Stellate Cells, Jundishapur J Nat Pharm Prod. 2017 ; 12(4):e40285. doi: 10.5812/jjnpp.40285.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830-41. doi: 10.1136/gutjnl-2014-306842. [PubMed: 25681399].
  • 2. Tu T, Calabro SR, Lee A, Maczurek AE, Budzinska MA, Warner FJ, et al. Hepatocytes in liver injury: Victim, bystander, or accomplice in progressive fibrosis?. J Gastroenterol Hepatol. 2015;30(12):1696-704. doi: 10.1111/jgh.13065. [PubMed: 26239824].
  • 3. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011;6:425-56. doi: 10.1146/annurev-pathol-011110-130246. [PubMed: 21073339].
  • 4. Friedman SL. Hepatic fibrosis -- overview. Toxicology. 2008;254(3):120-9. doi: 10.1016/j.tox.2008.06.013. [PubMed: 18662740].
  • 5. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134(6):1655-69. doi: 10.1053/j.gastro.2008.03.003. [PubMed: 18471545].
  • 6. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med. 2007;131(11):1728-34. doi: 10.1043/1543-2165(2007)131[1728:HSCALF]2.0.CO;2. [PubMed: 17979495].
  • 7. Weiskirchen R, Tacke F. Cellular and molecular functions of hepatic stellate cells in inflammatory responses and liver immunology. Hepatobiliary Surg Nutr. 2014;3(6):344-63. doi: 10.3978/j.issn.2304-3881.2014.11.03. [PubMed: 25568859].
  • 8. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 2004;99(2):271-9. [PubMed: 15046217].
  • 9. Cutroneo KR, White SL, Phan SH, Ehrlich HP. Therapies for bleomycin induced lung fibrosis through regulation of TGF-beta1 induced collagen gene expression. J Cell Physiol. 2007;211(3):585-9. doi: 10.1002/jcp.20972. [PubMed: 17387717].
  • 10. Rashid ST, Humphries JD, Byron A, Dhar A, Askari JA, Selley JN, et al. Proteomic analysis of extracellular matrix from the hepatic stellate cell line LX-2 identifies CYR61 and Wnt-5a as novel constituents of fibrotic liver. J Proteome Res. 2012;11(8):4052-64. doi: 10.1021/pr3000927. [PubMed: 22694338].
  • 11. Seki E, Brenner DA. Recent advancement of molecular mechanisms of liver fibrosis. J Hepatobiliary Pancreat Sci. 2015;22(7):512-8. doi: 10.1002/jhbp.245. [PubMed: 25869468].
  • 12. Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4(6):391-417. doi: 10.1177/1756283X11413002. [PubMed: 22043231].
  • 13. Duval F, Moreno-Cuevas JE, Gonzalez-Garza MT, Rodriguez-Montalvo C, Cruz-Vega DE. Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells. Adv Pharmacol Sci. 2014;2014:373295. doi: 10.1155/2014/373295. [PubMed: 25505905].
  • 14. Parveen R, Baboota S, Ali J, Ahuja A, Vasudev SS, Ahmad S. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage. Arch Pharm Res. 2011;34(5):767-74. doi: 10.1007/s12272-011-0510-8. [PubMed: 21656362].
  • 15. Zong L, Qu Y, Xu MY, Dong YW, Lu LG. 18alpha-glycyrrhetinic acid down-regulates expression of type I and III collagen via TGF-Beta1/Smad signaling pathway in human and rat hepatic stellate cells. Int J Med Sci. 2012;9(5):370-9. doi: 10.7150/ijms.4395. [PubMed: 22811611].
  • 16. Vaid M, Katiyar SK. Molecular mechanisms of inhibition of photocarcinogenesis by silymarin, a phytochemical from milk thistle (Silybum marianum L. Gaertn.) (Review). Int J Oncol. 2010;36(5):1053-60. [PubMed: 20372777].
  • 17. Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, et al. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther. 2011;33(1):127-37. doi: 10.1111/j.1365-2036.2010.04503.x. [PubMed: 21083592].
  • 18. Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, et al. Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology. 2010;138(2):671-81. doi: 10.1053/j.gastro.2009.09.021. [PubMed: 19782083].
  • 19. Agarwal C, Wadhwa R, Deep G, Biedermann D, Gazak R, Kren V, et al. Anti-cancer efficacy of silybin derivatives -- a structure-activity relationship. PLoS One. 2013;8(3):60074. doi: 10.1371/journal.pone.0060074. [PubMed: 23555889].
  • 20. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011;17(18):2288-301. doi: 10.3748/wjg.v17.i18.2288. [PubMed: 21633595].
  • 21. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs. 2001;61(14):2035-63. [PubMed: 11735632].
  • 22. Guo XL, Liang B, Wang XW, Fan FG, Jin J, Lan R, et al. Glycyrrhizic acid attenuates CCl(4)-induced hepatocyte apoptosis in rats via a p53-mediated pathway. World J Gastroenterol. 2013;19(24):3781-91. doi: 10.3748/wjg.v19.i24.3781. [PubMed: 23840116].
  • 23. Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015;62(2):627-34. doi: 10.1002/hep.27720. [PubMed: 25626988].
  • 24. Hong M, Li S, Tan HY, Wang N, Tsao SW, Feng Y. Current Status of Herbal Medicines in Chronic Liver Disease Therapy: The Biological Effects, Molecular Targets and Future Prospects. Int J Mol Sci. 2015;16(12):28705-45. doi: 10.3390/ijms161226126. [PubMed: 26633388].
  • 25. Esmaeilbeig M, Kouhpayeh SA, Amirghofran Z. An Investigation of the Growth Inhibitory Capacity of Several Medicinal Plants From Iran on Tumor Cell Lines. Iran J Cancer Prev. 2015;8(5):4032. doi: 10.17795/ijcp-4032. [PubMed: 26634114].
  • 26. Khanizadeh S, Ravanshad M, Hosseini S, Davoodian P, Nejati Zadeh A, Sarvari J. Blocking of SMAD4 expression by shRNA effectively inhibits fibrogenesis of human hepatic stellate cells. Gastroenterol Hepatol Bed Bench. 2015;8(4):262-9. [PubMed: 26468346].
  • 27. Trappoliere M, Caligiuri A, Schmid M, Bertolani C, Failli P, Vizzutti F, et al. Silybin, a component of sylimarin, exerts anti-inflammatory and anti-fibrogenic effects on human hepatic stellate cells. J Hepatol. 2009;50(6):1102-11. doi: 10.1016/j.jhep.2009.02.023. [PubMed: 19398228].
  • 28. Wen Z, Dumas TE, Schrieber SJ, Hawke RL, Fried MW, Smith PC. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos. 2008;36(1):65-72. doi: 10.1124/dmd.107.017566. [PubMed: 17913795].
  • 29. Gazak R, Walterova D, Kren V. Silybin and silymarin--new and emerging applications in medicine. Curr Med Chem. 2007;14(3):315-38. [PubMed: 17305535].
  • 30. Hsiang CY, Lin LJ, Kao ST, Lo HY, Chou ST, Ho TY. Glycyrrhizin, silymarin, and ursodeoxycholic acid regulate a common hepatoprotective pathway in HepG2 cells. Phytomedicine. 2015;22(7-8):768-77. doi: 10.1016/j.phymed.2015.05.053. [PubMed: 26141764].
  • 31. Zhao J, Wan X, Luo M, Chen T, He P. Antifibrotic effects of glycyrrhizin and matrine in vitro and in vivo. Biomedicine & Preventive Nutrition. 2012;2(2):132-7. doi: 10.1016/j.bionut.2011.12.006.
  • 32. Jia JD, Bauer M, Cho JJ, Ruehl M, Milani S, Boigk G, et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen alpha1(I) and TIMP-1. J Hepatol. 2001;35(3):392-8. [PubMed: 11592601].
  • 33. Di Sario A, Bendia E, Taffetani S, Omenetti A, Candelaresi C, Marzioni M, et al. Hepatoprotective and antifibrotic effect of a new silybin-phosphatidylcholine-Vitamin E complex in rats. Dig Liver Dis. 2005;37(11):869-76. doi: 10.1016/j.dld.2005.05.011. [PubMed: 16169303].
  • 34. Moro T, Shimoyama Y, Kushida M, Hong YY, Nakao S, Higashiyama R, et al. Glycyrrhizin and its metabolite inhibit Smad3-mediated type I collagen gene transcription and suppress experimental murine liver fibrosis. Life Sci. 2008;83(15-16):531-9. doi: 10.1016/j.lfs.2008.07.023. [PubMed: 18771671].
  • 35. Qu Y, Chen WH, Zong L, Xu MY, Lu LG. 18alpha-Glycyrrhizin induces apoptosis and suppresses activation of rat hepatic stellate cells. Med Sci Monit. 2012;18(1):BR24-32. [PubMed: 22207106].
  • 36. Clichici S, Olteanu D, Nagy AL, Oros A, Filip A, Mircea PA. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl(4)-treated rats. J Med Food. 2015;18(3):290-8. doi: 10.1089/jmf.2013.0179. [PubMed: 25133972].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments